Abstract:OBJECTIVE: To testify that the asialoorosomucoid (ASOR) prepared by us has liver‐targeting specificity and to investigate its pharmacokinetic characteristics.METHODS: The distribution of 125I‐ASOR in vivo was determined by single photon emission computed tomography (SPECT) and immunohistochemical technique after 125I‐ASOR was injected into Sprague‐Dawley (S–D) rats through their caudal veins. In vitro, different doses of pEGFP‐N1 plasmid were transfected into both HepG2 cells and HT1080 cells with the use of ASOR‐poly‐L‐lysine. At 24 and 48 h after transfection, the expression of green fluorescent protein (GFP) was determined under fluorescent microscope. Pharmacokinetic parameters were calculated according to two‐compartment open system model with first‐order kinetics.RESULTS: SPECT images showed that 125I‐ASOR was located only in liver/stomach and root of caudal vein / bladder at 10 min after injection. The 125I‐ASOR radioactivities of organs taken out from S–D rats were different at different times, and about 63% of 125I‐ASOR was located in the liver at 10 min after injection. At 30 min after injection a peak of radioactivity was seen in stomach. The times of these two radioactivity peaks were different. Immunohistochemical study of liver frozen sections showed that ASOR was combined mainly with hepatocyte membrane, especially in areas with rich blood flow. In vitro study showed that ASOR targeted specifically cells with asialoglycoprotein receptor (ASGr). GFP expression was detected in HepG2 cells but not in HT1080 cells. Furthermore, the more quantity of pEGFP‐N1 transfected and the longer expression time, the higher GFP expression level was in HepG2 cells. The 125I‐ASOR pharmacokinetics equation for liver was Ct = 662216e−3.362t + 8896e−2343t. 125I‐ASOR was excreted from liver slowly after an initial rapid decrease. The pharmacokinetic equation for stomach was Ct = –114815e−1.7t + 1148153e−15t and the half‐life of 125I‐ASOR in stomach was 4.62 h.CONCLUSIONS: ASOR prepared by us could be an efficient gene transfer vector, ASOR was distributed mainly in the liver and stomach and had high targeting specificity to hepatocytes or hepatic originating cells.

Distribution and metabodynamics of hepatocyte targeting vector molecules in vivo

Targeting Specificity and Pharmacokinetics of Asialoorosomucoid, a Specific Ligand for Asialglycoprotein Receptor on Hepatocyte

Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging

Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect.

Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis

Reduction of liver tumor necrosis factor-α expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis

Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging

In Vitroandin Vivostudies of Galactose-Modified Liver-Targeting Liposomes

Functional evaluation of poly-(N-ρ-vinylbenzyl-O-β-Dgalactopyranosyl-[1-4]-D-gluconamide)(PVLA) as a liver specific carrier

Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol

Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma

Selective in Vivo Targeting of Human Liver Tumors by Optimized Aav3 Vectors in A Murine Xenograft Model

[Liver Targeting of Cationic Liposomes Modified with Soybean-Derived Sterylglucoside in Vitro].

A bifunctional hepatocyte-mitochondrion targeting nanosystem for effective astaxanthin delivery to the liver

Modulation of the Molecular Conformation of a Hepatocyte-Targeting Gene Drug in Order to Improve Its Expression Efficiency in Vitro.

Organ/Cell-Selective Intracellular Delivery of Biologics via N -Acetylated Galactosamine-Functionalized Polydisulfide Conjugates

Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer

Modified ASO Conjugates Encapsulated with Cytidinyl/cationic Lipids Exhibit More Potent and Longer-Lasting Anti-Hcc Effects

Liver-targeting chimeras as a potential modality for the treatment of liver diseases

Identification and characterization of endogenous biomarkers for hepatic vectorial transport (OATP1B3-P-gp) function using metabolomics with serum pharmacology

Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector.